US 10722525
Targeted therapeutics
granted A61KA61K31/167A61K31/185
Quick answer
US patent 10722525 (Targeted therapeutics) held by Madrigal Pharmaceuticals, Inc. expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Madrigal Pharmaceuticals, Inc.
- Grant date
- Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K31/167, A61K31/185, A61K31/4184, A61K31/4196